

## RITA Medical Systems Announces Second Quarter 2006 Earnings Release Date and Conference Call

FREMONT, Calif., July 20 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (Nasdaq: RITA) today announced that it will release financial results for the second quarter ended June 30, 2006, after the market close on Tuesday, August 8, 2006. The Company will also host a conference call and live audio webcast on Tuesday, August 8, 2006 at 2:00 p.m. Pacific Time to discuss the Company's second quarter results, outlook for the remainder of 2006, and current corporate developments. The dial-in number for the conference call is 800-257-1836 for domestic participants and 303-205-0066 for international participants. A live audio webcast of the conference call will also be available at [www.ritamedical.com](http://www.ritamedical.com).

A taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will remain available for 7 days. It can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using the passcode 11066571#.

An online replay of the audio webcast will be available immediately following the broadcast at [www.ritamedical.com](http://www.ritamedical.com). Webcast participants are encouraged to go to the site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.

About RITA Medical Systems, Inc.

RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company distributes the LC Bead™ (Biocompatibles, UK) product which is used in arterial embolization of hypervascular tumors and arteriovenous malformations and has U.S. Food and Drug Administration (FDA) marketing clearance in the U.S. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; and safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The product line also includes the HABIB 4X resection device which coagulates a surgical resection plane and is designed to facilitate a fast dissection in order to minimize blood loss and blood transfusion during surgery. The proprietary RITA RFA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time for the palliation of pain associated with metastatic lesions involving bone. The RITA Medical Systems website is at [www.ritamedical.com](http://www.ritamedical.com). The Company cautions the reader that the planned appearances of Company personnel, time and/or manner of the live teleconference, webcast and replays may change for administrative or other reasons outside the Company's control.

SOURCE RITA Medical Systems, Inc. 07/20/2006

CONTACT: Stephen Pedroff, VP Marketing Communications of RITA Medical Systems, Inc., +1-510-771-0400, or [spedroff@ritamed.com](mailto:spedroff@ritamed.com);  
or media,  
Steve DiMattia, +1-646-277-8706, or [sdimattia@evcgroup.com](mailto:sdimattia@evcgroup.com),  
or investors,  
Doug Sherk, +1-415-896-6820, or [dsherk@evcgroup.com](mailto:dsherk@evcgroup.com),  
or Jennifer Beugelmans, +1-415-896-6820, all of EVC Group, f  
or RITA Medical Systems, Inc.  
Web site: <http://www.ritamedical.com>  
(RITA)